The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The US generic injectables market was valued at US$ 16.3 Billion in 2021.
We expect the US generic injectables market to exhibit a CAGR of 10.21% during 2022-2027.
The sudden outbreak of the COVID-19 pandemic has led to the easy availability of generic injectables via online pharmacies with free doorstep delivery, to combat the risk of the coronavirus infection across the nation.
The rising utilization of generic injectables in treating various cardiovascular disorders without affecting the efficacy of the treatment is primarily driving the US generic injectables market.
Based on the therapeutic area, the US generic injectables market can be segmented into oncology, anesthesia, anti-Infectives, parenteral nutrition, and cardiovascular. Among these, oncology holds the majority of the total market share.
Based on the containers, the US generic injectables market has been divided into vials, ampoules, premix, and prefilled syringes, where vials currently exhibit a clear dominance in the market.
Based on the distribution channel, the US generic injectables market can be segregated into hospitals and retail pharmacy. Currently, hospitals account for the largest market share.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at